Wordt geladen...
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3‐Mutated AML
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients....
Bewaard in:
| Gepubliceerd in: | Oncologist |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869119/ https://ncbi.nlm.nih.gov/pubmed/33368797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13652 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|